Drug Database
RH

Rho(D) Immune Globulin

✓ Approved

CSL Limited · 多克隆抗体 · 多克隆抗体

什么是 Rho(D) Immune Globulin?

Rho(D) Immune Globulin 是一种多克隆抗体,由CSL Limited研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

公司CSL Limited
药物类别多克隆抗体, 抗体
给药途径Injectable (Others), Intravenous (IV)
状态Approved

治疗适应症

Rho(D) Immune Globulin 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Congenital, familial and genetic disordersRhesus haemolytic disease of newborn✓ Approved

相关研究文献

PubMedbioRxiv : the preprint server for biology2026-11-20

SWELL1 channel-mediated D-2HG export promotes immune evasion and metabolic fitness in IDH-mutant gliomas.

Cheng Henry Yi HY, Ma Lifei L, Chen Jianan J, Huang Jiale J et al.

Isocitrate dehydrogenase (IDH) is the most frequently mutated metabolic enzyme in human cancers. Mutant IDH produces D-2-hydroxyglutarate (D-2HG), which promotes tumorigenesis through epigenetic alterations. Beyond cell-autonomous effects, tumor-derived D-2HG acts as a potent immunosuppressant that establishes an immune-cold tumor microenvironment (TME). However, the mechanism by which D-2HG is released from tumors remains largely unknown. Here, we identify the SWELL1 (LRRC8A)/LRRC8C-containing volume-regulated anion channel (VRAC) as a principal pathway for D-2HG efflux from IDH-mutant cells. Deletion of SWELL1, the essential VRAC subunit, markedly reduces D-2HG release and reverses associated immunosuppression in an orthotopic mouse model of IDH-mutant glioma. Strikingly, VRAC loss causes intracellular D-2HG accumulation, which paradoxically limits glioma proliferation by driving epigenetic remodeling and mitochondrial metabolic stress. Pharmacological VRAC inhibition with dicumarol suppresses IDH-mutant glioma growth, enhances intratumoral T cell activation, synergizes with immune checkpoint blockade, and prolongs survival in tumor-bearing mice. In human IDH-mutant lower-grade gliomas, elevated LRRC8C expression correlates inversely with DNA hypermethylation and positively with an immunosuppressive TME, and is associated with poor survival. Together, these findings establish VRAC-mediated D-2HG export as a previously unrecognized D-2HG clearance pathway that promotes both immune evasion and tumor cell fitness, uncovering new therapeutic opportunities beyond direct inhibition of D-2HG synthesis.

PMID 43059728
阅读全文 →
PubMedFrontiers in medicine2026-11-20

Immune escape biomarkers in chondrosarcoma: implications for PD-1/PD-L1 blockade and precision combination therapy.

Chi Yingjun Y

Chondrosarcoma is a biologically heterogeneous bone malignancy for which surgery remains the principal curative treatment, while systemic options for unresectable or metastatic disease are limited. Immune checkpoint blockade has produced occasional durable responses, particularly in dedifferentiated chondrosarcoma, but clinical activity is inconsistent and validated treatment-selection biomarkers are lacking. This Mini Review synthesizes chondrosarcoma-specific evidence on PD-L1, CD8-positive tumor-infiltrating lymphocytes, HLA class I (HLA-I)/β2-microglobulin integrity, the CD68/CD8 ratio, CSF1R-positive tumor-associated macrophages (TAMs), granulocytic myeloid-derived suppressor cells (G-MDSCs), B7-H3, and immune-phenotype classification. These markers capture complementary immune-escape processes but are largely descriptive, prognostic, or mechanistic rather than prospectively validated predictors of checkpoint-inhibitor benefit. IDH1/2 mutations and D-2-hydroxyglutarate (D-2HG) provide an additional metabolic framework, although direct evidence connecting D-2HG with immune escape in chondrosarcoma remains incomplete. The multicenter, non-randomized phase 2 FLAIL-C study reported higher 6-month progression-free survival with anti-PD-1 plus anlotinib than with anlotinib alone, particularly in dedifferentiated disease; its non-randomized design limits causal interpretation. Future subtype-stratified trials should test composite, spatially informed panels and assess mutant-IDH inhibition, myeloid modulation, and B7-H3-directed cellular therapy, the last of which remains preclinical in chondrosarcoma.

PMID 43061336
阅读全文 →
PubMedBMC infectious diseases2026-11-20

A matter of time: impact of time to first follow-up blood cultures in patients with candidemia and Staphylococcus aureus bacteremia from a retrospective cohort.

Valsecchi Pietro P, Bono Enrica E, Valeretto Alessia A, Resuli Semela S et al.

Guidelines recommend performing follow-up blood cultures (FUBCs) in patients with Staphylococcus aureus bacteraemia (SAB) and candidemia due to increased mortality in persistent infections, but their impact on length of stay (LOS), length of treatment (LOT), and time to the first negative FUBCs has been less described. Patients admitted to our Institution with SAB or candidemia were included. Correlation between time to first FUBCs and outcomes were performed using Spearman rank test. We performed survival analysis using a multivariate Cox regression model. Patients dying before 72 h were excluded to limit survival bias. The study included 217 patients with SAB and 138 patients with candidemia. The correlation between time to first FUBCs and LOS was statistically significant for SAB (rho =0,19; p value 0,05), but not for candidemia (rho= 0,37; p value 0,08). Time to first FUBCs correlated significantly with LOT in both groups (SAB rho =0,31; p value =0,02; candidemia rho=0,37; p value <0,001) and first negative FUBCs (SAB rho =0,88; p value <0,001; candidemia rho=0,66; p value <0,001). In multivariate Cox regression model, FUBCs within 48 hours (HR 0,26 (0,07 - 0,91), p value 0,04) were associated with improved survival for SAB, while not performing FUBCs (HR 3,31 (1,04 - 10,60), p value 0,02) affected survival in patients with candidemia. These results show that delaying FUBCs was associated with a deleterious impact on LOT, LOS, and culture clearance. Furthermore, our findings highlight the importance of timely follow-up blood cultures within the integrated care of these infections, together with source control, effective antimicrobial therapy, and infectious disease consultation to improve survival.

PMID 43058520
阅读全文 →
PubMedAllergologia et immunopathologia2026-11-20

High prevalence of hypovitaminosis D in Mexican children with atopic dermatitis: A cross-sectional study.

Torruco-Vera Alejandro A, Gonzalez-Uribe Victor V, Prieto-Gomez Jimena J, Martinez-Tenopala Ricardo R et al.

Vitamin D has been implicated in epidermal barrier function and immune regulation, but its clinical relevance in pediatric atopic dermatitis (AD) remains uncertain. This retrospective cross-sectional study aimed to determine the prevalence of vitamin D insufficiency and deficiency in Mexican children with AD and to explore its association with disease severity in a tertiary-care setting. Patients aged 6 months to 17 years evaluated between January 2022 and January 2023 were included if they had a diagnosis of AD and an available serum 25-hydroxyvitamin D measurement. Disease severity was assessed using the SCORing Atopic Dermatitis index. A total of 423 patients were analyzed; 223 (52.7%) had mild disease, 178 (42.1%) had moderate disease, and 22 (5.2%) had severe disease. Only 23 patients (5.4%) had sufficient vitamin D levels, whereas 273 (64.5%) had insufficiency and 127 (30.0%) had deficiency. The distribution of categorical vitamin D status did not differ significantly across severity strata. Serum vitamin D levels differed modestly across severity groups, with the lowest mean concentration observed in severe disease. In the full cohort, serum vitamin D levels were not independently associated with SCORAD after age adjustment. In an exploratory analysis restricted to moderate-to-severe disease, lower vitamin D levels were associated with higher SCORAD values. Hypovitaminosis D was highly prevalent in this Mexican pediatric cohort with AD. Its relationship with disease severity appears nonuniform and should be interpreted cautiously in light of the cross-sectional design.

PMID 43062429
阅读全文 →
PubMedZhongguo shi yan xue ye xue za zhi2026-11-20

[Analysis of RHD Gene Polymorphism and Construction of a Genotype-Risk Stratification Model].

Li Jun J, Chen Zi-Qi ZQ, Wang Lan L, Cui Yan Y et al.

To systematically analyze the characteristics of RhD-negative and RhD variant mutations and their effects on D epitopes in this region, and construct a genotype-risk stratification model based on the molecular mechanism of different genotypes, antigen expression intensity, and clinical immune risk, so as to provide a basis for clinical blood transfusion and pregnancy management in RhD-negative and RhD variant populations. A total of 108 RhD-negative and RhD variant cases (4 cases of repeated detection were excluded) from January 2023 to March 2025 were enrolled in this way, including 13 males and 95 females. Serologic RhD-negative confirmation tests were performed on those who were initially screened negative by the microcolumn gel, and those who were negative in the RhD-negative confirmation test were subjected to the absorption and release test. RhD-negative or RhD variant samples were subjected to DNA extraction, PCR amplification, and gene sequencing. A genotype-risk stratification model was constructed based on the molecular mechanism of different genotypes, antigen expression intensity, and clinical immune risk. No anti-D antibodies were detected in 13 males. 11 of the 95 females were positive for anti-D antibody. Among them, anti-D antibody were detected in 7 cases with RHD*01N.01, 1 case with RHD*01N.03, 2 cases with RHD*01N.04, and 1 case with RHD*15. A total of 5 Rh phenotypes were detected in this study, with ccee accounting for 52.78% (57/108), Ccee accounting for 33.33% (36/108), ccEe accounting for 10.19% (11/108), CCee accounting for 2.78% (3/108), and CcEe accounting for 0.93% (1/108). RHD*01N.01 was closely related to the ce gene, and RHD*01EL.01 was highly linked to Ce gene. A total of 8 RHD genotypes were detected in this study. In 86 cases of RHD-negative genes, the detection rates from high to low were 65.74% (71/108) for RHD*01N.01, 6.48% (7/108) for RHD*01N.04, 4.63% (5/108) for RHD*01N.03, and 2.78% (3/108) for RHD*01N.16. In 22 cases of RHD variant genes, the detection rates from high to low were 14.81% (16/108) for RHD*01EL.01, 3.70% (4/108) for RHD*15, 0.93% (1/108) for RHD*95A, and 0.93% (1/108) for RHD*06.03.01. Genotype-risk stratification model: RHD*15 and RHD*06.03.01 with the risk of being immunized by D-positive and immunized D-negative were divided into high-risk group and strictly managed. RHD*95A individuals had an immune risk but a low probability of antibody production, and they were classified into the medium-risk group to devise individualized strategies. RhD-negative management according to D-negative and DEL type according to D-positive management evidence were clear, so they were classified into low-risk group. RHD genes in this region have unique polymorphisms, and the molecular mechanisms of different genotypes have different effects on protein structure. The construction of genotype-risk stratification model can realize the precise transformation from laboratory to clinic, thus possibly providing a reference for improving the safety of blood transfusion and pregnancy management.

PMID 43059248
阅读全文 →
PubMedPediatric blood & cancer2026-11-20

Timing of Eltrombopag Initiation and Treatment-Free Remission in Children With Persistent and Chronic Immune Thrombocytopenia: A Retrospective Tertiary-Center Cohort Study.

İzmir Muhammed Ata MA, Küpesiz Alphan A, Güler Elif E, Küpesiz Funda Tayfun FT

Eltrombopag is an established second-line therapy for children with persistent or chronic immune thrombocytopenia (ITP), but treatment-free remission after discontinuation and its relationship with treatment timing remain insufficiently defined. We evaluated eltrombopag outcomes, focusing on initiation timing and time to treatment-free remission. This retrospective tertiary-center cohort included children with persistent or chronic ITP followed from December 2014 to December 2024. Of 81 patients, 41 received eltrombopag. Treatment-free remission was defined as maintaining a platelet count ≥50 × 109/L for at least six consecutive months without ITP-directed treatment and without bleeding or other clinical symptoms. Persistent- versus chronic-phase initiation was compared using Kaplan-Meier analysis and the log-rank test. Overall, platelet response was achieved in 36/41 patients (88%), sustained platelet response in 23/41 (56%), and treatment-free remission in 14/41 (34%). In the 40-patient timing cohort, time to treatment-free remission was shorter with persistent-phase initiation than with chronic-phase initiation (log-rank p = 0.027); Kaplan-Meier estimated median times were 28 and 78 months, respectively. Among patients achieving treatment-free remission, a longer diagnosis-to-eltrombopag interval was associated with a longer eltrombopag-to-remission interval (rho = 0.543, p = 0.045, n = 14). Adverse events occurred in 8/41 patients (20%), with no permanent discontinuations. Eltrombopag was associated with high platelet response rates and treatment-free remission in approximately one-third of treated children. Persistent-phase initiation was associated with shorter time to treatment-free remission than chronic-phase initiation. Prospective multicenter studies are needed to determine whether earlier eltrombopag initiation is associated with a higher likelihood of, or shorter time to, treatment-free remission.

PMID 43061894
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多Rho(D) Immune Globulin